跳至主要内容
临床试验/NCT01404923
NCT01404923已完成4 期

Assessment of On-demand MeteoSpasmyl® Use Effectiveness in Irritable Bowel Syndrome

Laboratoires Mayoly Spindler0 个研究点目标入组 436 人开始时间: 2009年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
436
主要终点
Change From Baseline in Irritable Bowel Syndrome Quality Of Life Overall Score

研究概览

简要总结

The purpose of this study is to compare the effectiveness of 2 IBS treatment strategies:

  • Strategy A = MeteoSpasmyl®, on-demand therapy
  • Strategy B = standard of care chosen by the physician

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • male or female ambulatory patients, aged >= 18 years
  • with IBS as defined by Rome III criteria for more than 1 year and less than 10 years
  • with a IBS-SSS between 175 and 400

排除标准

  • Acute diarrhea, bowel disorders due to an underlying cause
  • Patient treated with MeteoSpasmyl® within the past 6 months
  • Recent history of gastro intestinal surgery

研究组 & 干预措施

meteospasmyl

Experimental

干预措施: alverine citrate, simeticone (Drug)

standard of care

Active Comparator

干预措施: anti spasmodic agents (Drug)

结局指标

主要结局

Change From Baseline in Irritable Bowel Syndrome Quality Of Life Overall Score

时间窗: Baseline and 6 months

Irritable Bowel Syndrome Quality of Life total score (IBSQoL) is a health-related Quality of Life (QoL) disease-specific scale adapted for French patients. Total score ranges from minimum=0 to maximum = 100 representing the best outcome.

Percentage of Improvement of the Total IBSQoL Scores

时间窗: Baseline and 6 Months

Improvement of the total IBSQoL scores from baseline to month 6 calculated in percentage

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验

Effectiveness of On-demand Meteospasmyl® Use in... | 临床试验